PlaqueTec has validated the LBS in two clinical studies and identified numerous biomarkers associated with CAD and specific drug treatments.
In the first study, the safety of sampling from within human coronary arteries was demonstrated.
In the second study, a large set of plaque biomarkers was identified, each a fingerprint for a key CAD biological process.
In addition to the identification of biomarkers associated with the CAD disease pathology and with specific drug treatments, the company is building a biobank of samples from a full spectrum of CAD patient groups. These unique samples are enabling, for the first time, the mapping of the exact biological signals that drive the disease pathways in the most critical zone of the heart.